TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A review in Nutrients examines research on ergothioneine, an antioxidant found in mushrooms and other foods, and its possible effects on brain health. Some human studies link lower blood levels with poorer cognition, but the evidence does not show that eating mushrooms prevents dementia or that supplements delay disease.
A review published in Nutrients has assessed whether ergothioneine, a naturally occurring antioxidant found in mushrooms and other foods, could help protect the aging brain. Researchers at the University of Rzeszow in Poland describe suggestive findings from observational, laboratory and animal studies, but say the evidence does not establish that eating more mushrooms prevents neurodegenerative disease.
The review examined studies linking blood levels of ergothioneine, or ET, with cognition and conditions including Alzheimer’s and Parkinson’s disease. Several observational studies reported that lower circulating ET levels were associated with poorer cognitive performance or a higher likelihood of disease. In one longitudinal study of 470 people who did not have cognitive impairment at the outset, lower ET was associated with faster decline across measures including global cognition, attention, memory, locomotion and language.
Other research summarized in the review found lower blood ET in older adults with mild cognitive impairment than in age-matched healthy participants, and lower serum levels among people with Parkinson’s disease than among healthy controls. A study examining 991 blood metabolites and cognition found ET had the strongest reported association with cognitive performance. These are associations, not proof of cause: the review notes that low levels might contribute to disease, or might reflect increased antioxidant use during oxidative stress. It also cites conflicting research, including a study that linked higher serum ET to increased Alzheimer’s risk.
Experiments in cells and animals offer possible explanations for a protective effect. ET treatment reduced reactive oxygen species and improved cell survival in some laboratory models, while studies in mice and other models reported less cognitive or behavioral impairment. However, the researchers caution that some cell experiments used concentrations unlikely to be reached in people, and animal studies often used doses higher than typical dietary intake. The review also discusses possible anti-inflammatory activity and activation of Nrf2, a regulator of the body’s antioxidant response.
What the Evidence Means for Diet
The findings add to research into how diet-related compounds might relate to brain aging, but they do not justify treating mushrooms as a proven way to prevent dementia. No cure currently exists for neurodegenerative diseases, and the review describes ET as a possible area for further study, not an established preventive treatment. For readers, the distinction matters: a nutrient’s presence in a food and a relationship between blood levels and health do not by themselves show that increasing intake changes disease risk.
Human trials summarized in the review provide limited, mixed signals. ET administration for as long as 35 days was associated with downward trends in some blood and urine markers of inflammation and oxidative damage, but those changes were not statistically significant. A 16-week trial reported a temporary improvement in a composite memory measure at week four among participants receiving the higher dose. Another 12-week trial using mushroom extract tablets reported improved verbal memory in healthy participants and people with suspected mild cognitive impairment. Because the tablets contained mushroom extract, the review says other compounds may have contributed.
These results do not establish that ordinary servings of mushrooms produce the same effects as concentrated extracts or supplements. Nor do short-term changes in sleep or memory prove that ET prevents or delays a progressive disease. The review’s value is in mapping a plausible research direction while making clear that clinical benefit remains uncertain.
Products Worth Considering
EGO POWER+ String Trimmer, Battery Powered, 16 Trimmer for Weeds and Grass with POWERLOAD, LINE IQ, Telescopic Carbon Fiber Shaft, Battery a
Husqvarna Automower 550 Commercial Robotic Lawn Mower
Rachio 3 Smart Sprinkler Controller, 8-Zone
As an affiliate, we earn on qualifying purchases.
How Ergothioneine Reached the Research
Ergothioneine is a thiol antioxidant found in mushrooms and some other foods. Researchers have studied it because oxidative stress is associated with neurodegenerative disease and may contribute to damage in the brain. Antioxidants have consequently been proposed as possible protective agents, though that rationale alone does not establish that a particular antioxidant will prevent disease in people.
Earlier research had proposed that inadequate dietary ET might contribute to neurodegeneration. The review describes that idea as a hypothesis that remains unproven. Its authors brought together evidence about ET levels, supplementation, and proposed biological mechanisms, including antioxidant and anti-inflammatory effects. The evidence spans different kinds of studies, from observations of blood levels in people to experiments in cells and animals, so results cannot be treated as interchangeable.
Human studies cited in the review include short trials of ET supplements and mushroom extracts. One trial gave 20 milligrams of ET per day for four weeks to people with sleep complaints and anxiety and reported improvement in sleeping difficulties. Another reported better subjective sleep quality after 16 weeks among people aged 40 to 64 who were aware of attention or memory decline. The review notes that sleep disturbances can precede motor symptoms in Parkinson’s disease, but the suggestion that ET might delay disease onset is not proven in humans.
“Dietary ET deficiency may contribute to neurodegeneration, a hypothesis that remains unproven.”
— The University of Rzeszow researchers, as summarized in the Nutrients review
What Human Studies Still Cannot Show
The reviewed evidence does not answer whether raising ET intake prevents cognitive decline, reduces the risk of Alzheimer’s or Parkinson’s, or delays disease onset. Observational studies cannot determine whether low ET is a cause or consequence of illness, and one study reported the opposite direction of association for Alzheimer’s risk. The findings are not consistent enough to settle the relationship.
Supplement trials were generally short and examined outcomes such as sleep, memory measures or biomarkers rather than whether participants later developed neurodegenerative disease. Some results were temporary, statistically nonsignificant or based on mushroom extracts containing compounds besides ET. It is also unclear whether the amounts used in supplements can be matched by eating mushrooms as part of an ordinary diet. The review does not establish a recommended intake or show that supplementation is safe and effective for preventing brain disease over the long term.
Evidence Needed Before Dietary Claims
The review points to the need for stronger human research that can test whether ET itself affects cognition or disease risk. Longer and larger trials would need to distinguish ET from other compounds in mushroom products, use doses relevant to human diets, and track meaningful health outcomes rather than relying only on short-term biomarkers or self-reported changes. Studies would also need to clarify how blood ET levels relate to intake and to changes in health over time.
Until such evidence is available, the review supports further investigation rather than a claim that more mushrooms protect the brain. The next milestone is not a confirmed dietary recommendation, but research capable of determining whether the observed associations translate into a measurable benefit for people.
Key Questions
Does eating more mushrooms prevent dementia?
No. The review does not show that eating mushrooms prevents dementia. It assesses early research on ergothioneine, including associations and experimental findings, but prevention has not been established in people.
What is ergothioneine?
Ergothioneine, or ET, is a naturally occurring thiol antioxidant found in mushrooms and other foods. Researchers are studying its possible antioxidant and anti-inflammatory effects.
Do lower ET levels cause cognitive decline?
That is unknown. Some studies found that lower blood ET was associated with poorer cognition or faster decline, but observational findings cannot tell whether low levels contribute to disease or result from it. The review also cites conflicting results.
Have ET supplements improved memory in people?
Some short human trials reported improvements in selected memory or sleep measures. The findings are limited: one memory improvement was temporary, and a mushroom extract trial could not establish that ET alone caused the result. These studies do not show that supplements prevent neurodegenerative disease.
Source: news-medical.net
